Gross margin at 86.2% reflects Vertex's near-monopoly in cystic fibrosis — Trikafta/Kaftrio treats ~90% of the CF population with no comparable alternative. This is not software economics; this is monopoly-priced small molecules with established manufacturing. The filing acknowledges 'substantially all our net product revenues have been derived from the sale of our CF medicines,' confirming the concentration that enables this margin.

OCF of $3.6B at 0.9x net income of $4.0B is healthy — the slight discount reflects ongoing investment in clinical programs and working capital needs for CASGEVY's complex cell therapy manufacturing. For a biopharma with active pipeline investment, cash conversion at 90% of earnings is strong evidence that reported profits represent real economic value.

FCF of $3.2B represents a 26.7% FCF margin, funding both pipeline R&D and shareholder returns. FCF is 80% of net income — the gap reflects manufacturing expansion for new modalities (cell therapy, gene therapy) that are more capital-intensive than small molecule CF medicines.

Revenue of $12.0B from essentially a single disease franchise (CF) is remarkable. Trikafta's combination of clinical superiority, patient lock-in (lifelong treatment), and global expansion continue to drive growth even in a relatively small (~90,000 treatable patient) addressable market, demonstrating extreme value capture per patient.

ROE at 21.2% is excellent for biopharma, reflecting Vertex's ability to generate outsized returns on equity without excessive leverage. With only 4.2% goodwill/assets, the equity base is clean — this is genuine return on invested capital, not acquisition-inflated distortion.

The filing states 'substantially all our net product revenues have been derived from the sale of our CF medicines' and warns that 'we may be unable to sustain or increase revenues from sales of our CF medicines in the future for any number of reasons, including the potential introduction of competitive products.' The current reality: Trikafta treats ~90% of CF patients globally with no approved competitor of comparable efficacy, creating near-absolute pricing power.

86.2% gross margin on manufactured pharmaceuticals is the clearest pricing power indicator. For context, most biopharma companies with marketed drugs achieve 70-80% gross margins. Vertex's premium reflects monopoly economics: CF patients and their physicians have no alternative of comparable efficacy, making price sensitivity minimal.

FCF margin of 26.7% ($3.2B/$12.0B) funds both aggressive pipeline R&D and manufacturing expansion for new modalities. The margin is strong for a company simultaneously investing in small molecules (pain), cell therapy (CASGEVY), and gene therapy platforms.

FCF at 80% of net income reflects deliberate reinvestment: manufacturing infrastructure for CASGEVY's cell therapy is significantly more capital-intensive than CF pill manufacturing. The filing acknowledges 'the cost of manufacturing CASGEVY as a percentage of revenue is significantly higher than for our CF medicines.' This investment is necessary for pipeline-driven growth.

Goodwill at 4.2% of assets is minimal, confirming Vertex's growth has been overwhelmingly organic. The CF franchise was built through internal R&D (starting with ivacaftor through to elexacaftor/tezacaftor/ivacaftor), not through acquisitions. Clean balance sheet with no impairment risk.

Vertex's capital allocation prioritizes R&D across multiple therapeutic modalities: CF next-generation treatments, NaV1.7/1.8 pain inhibitors, CASGEVY cell therapy, and kidney disease programs. The filing's risk factors section reveals the breadth of clinical-stage programs, confirming management is deploying CF cash flows into pipeline diversification.